Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis
KM McKown, LD Carbone, SB Kaplan… - … : Official Journal of …, 1999 - Wiley Online Library
KM McKown, LD Carbone, SB Kaplan, JA Aelion, KM Lohr, MA Cremer, J Bustillo…
Arthritis & Rheumatism: Official Journal of the American College …, 1999•Wiley Online LibraryObjective To investigate the efficacy of oral type II collagen (CII) in the treatment of
rheumatoid arthritis (RA), when added to existing therapy. Methods Patients with active RA
(n= 190) were randomized into a 6‐month, double‐blind, placebo‐controlled trial. Patients
continued to take their current arthritis medications. Patients received either placebo or
bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results There were no
significant differences between the baseline characteristics of either group. The primary …
rheumatoid arthritis (RA), when added to existing therapy. Methods Patients with active RA
(n= 190) were randomized into a 6‐month, double‐blind, placebo‐controlled trial. Patients
continued to take their current arthritis medications. Patients received either placebo or
bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results There were no
significant differences between the baseline characteristics of either group. The primary …
Objective
To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy.
Methods
Patients with active RA (n = 190) were randomized into a 6‐month, double‐blind, placebo‐controlled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months.
Results
There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group.
Conclusion
Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.
Wiley Online Library